Skip to main content
. 2022 May 7;12(5):1170. doi: 10.3390/diagnostics12051170

Figure 1.

Figure 1

Kaplan–Meier estimates of (a) time to progression and (b) overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization according to their neutrophil-to-lymphocyte ratio (NLR) and FIB-4 levels. Group 1, NLR < 1.7 and FIB-4 < 3.0; Group 2, NLR ≥ 1.7 and FIB-4 < 3.0 or NLR < 1.7 and FIB-4 ≥ 3.0; Group 3, NLR ≥ 1.7 and FIB-4 ≥ 3.0.